Immuneering Q1 net loss $13.5M; cash $198.6M; Phase 3 pancreatic trial recruiting; ASCO data June 1

Immuneering Corp

Q1 2026 net loss $13.5M ($0.21 per share) vs $15.0M ($0.42 per share) in Q1 2025.
Cash, equivalents and marketable securities $198.6M (Dec 31, 2025: $217.0M); runway into 2029.
R&D expenses $10.6M (down from $11.5M YoY); G&A expenses $4.7M (up from $4.0M).
Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer now recruiting; first patient dosing mid-2026.
Updated survival data from Phase 2a cohort (55 patients) to be presented in oral session at ASCO June 1, 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.